Evidence map›Paper›PMID 33205401›Full record

ArticleClinical and experimental immunology2021

Expansion of immature, nucleated red blood cells by transient low-dose methotrexate immune tolerance induction in mice.

J Q Tran, D Grover, M Zhang, M Stapels, R Brennan, D S Bangari, P A Piepenhagen, E Roberts, P Oliva, F Zubair and 3 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and experimental immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 81% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

J Q TranSanofi Translational Sciences Bioinformatics, 270 Albany St, Cambridge, MA, 02139, USA
D GroverSanofi Translational Sciences Bioinformatics, 270 Albany St, Cambridge, MA, 02139, USA
M ZhangSanofi Translational Sciences Bioinformatics, Cambridge, MA, USA.
M StapelsSanofi Biologics Development, Cambridge, MA, USA.
R BrennanSanofi Preclinical Safety, Cambridge, MA, USA.
D S BangariSanofi Translational In Vivo Models, Cambridge, MA, USA.
P A PiepenhagenSanofi Translational In Vivo Models, Cambridge, MA, USA.
E RobertsSanofi Translational In Vivo Models, Cambridge, MA, USA.
P OlivaSanofi Translational Sciences Bioinformatics, 270 Albany St, Cambridge, MA, 02139, USA
F ZubairSanofi Translational Sciences Bioinformatics, 270 Albany St, Cambridge, MA, 02139, USA
J L VelaSanofi Translational Sciences Bioinformatics, 270 Albany St, Cambridge, MA, 02139, USAORCID 0000-0003-3072-6366
S M RichardsSanofi Translational Medicine and Early Development, Cambridge, MA, USA.
A M JosephSanofi Translational Sciences Bioinformatics, 270 Albany St, Cambridge, MA, 02139, USA
Sanofi (United States) · US

Funding

Sanofi
6 · The paper itself

Abstract

Biological treatments such as enzyme-replacement therapies (ERT) can generate anti-drug antibodies (ADA), which may reduce drug efficacy and impact patient safety and consequently led to research to mitigate ADA responses. Transient low-dose methotrexate (TLD-MTX) as a prophylactic ITI regimen, when administered concurrently with ERT, induces long-lived reduction of ADA to recombinant human alglucosidase alfa (rhGAA) in mice. In current clinical practice, a prophylactic ITI protocol that includes TLD-MTX, rituximab and intravenous immunoglobulin (optional), successfully induced lasting control of ADA to rhGAA in high-risk, cross-reactive immunological material (CRIM)-negative infantile-onset Pompe disease (IOPD) patients. More recently, evaluation of TLD-MTX demonstrated benefit in CRIM-positive IOPD patients. To more clearly understand the mechanism for the effectiveness of TLD-MTX, non-targeted transcriptional and proteomic screens were conducted and revealed up-regulation of erythropoiesis signatures. Confirmatory studies showed transiently larger spleens by weight, increased spleen cellularity and that following an initial reduction of mature red blood cells (RBCs) in the bone marrow and blood, a significant expansion of Ter-119

Indexed as

alpha-GlucosidasesAnimalsCell DifferentiationCell ProliferationDose-Response Relationship, DrugErythroblastsErythrocytesErythropoiesisFemaleGene Expression ProfilingHumansImmune ToleranceImmunosuppressive AgentsMethotrexateMiceMice, Inbred C57BLalpha-GlucosidasesGAA protein, humanImmunosuppressive AgentsMethotrexateerythropoiesistolerance inductiontransient methotrexate

Identifiers

PMID33205401
PMCPMC7874831
OpenAlexW3101878491

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.